Andreas Argyrides
Stock Analyst at Chardan Capital
(4.42)
# 1,213
Out of 4,978 analysts
376
Total ratings
47.2%
Success rate
10.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRD Opus Genetics | Rated: Buy | $13 → $16 | $5.41 | +195.75% | 3 | Sep 9, 2026 | |
| EYPT EyePoint | Downgraded: Hold | $65 → $5 | $3.45 | +44.93% | 2 | Aug 18, 2026 | |
| RANI Rani Therapeutics Holdings | Initiated Coverage: Buy | $6 | $0.756 | +693.65% | 14 | Aug 18, 2026 | |
| AQST Aquestive Therapeutics | Reiterated: Buy | $8 | $4.82 | +65.98% | 20 | Jun 25, 2026 | |
| SVRA Savara | Reiterated: Buy | $11 | $5.13 | +114.42% | 6 | Jun 3, 2026 | |
| BNTC Benitec Biopharma | Rated: Hold | n/a | $11.07 | - | 3 | May 11, 2026 | |
| GOSS Gossamer Bio | Rated: Hold | n/a | $10.96 | - | 19 | May 11, 2026 | |
| KROS Keros Therapeutics | Rated: Hold | n/a | $10.74 | - | 17 | May 11, 2026 | |
| LQDA Liquidia | Rated: Hold | n/a | $68.45 | - | 17 | May 11, 2026 | |
| LRMR Larimar Therapeutics | Rated: Hold | n/a | $3.93 | - | 8 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.46 | - | 28 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $101.45 | - | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.17 | - | 18 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $498.48 | - | 19 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.55 | - | 8 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $105 → $98 | $77.64 | +26.22% | 5 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $17.31 | +131.15% | 7 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $62 | $42.21 | +46.88% | 2 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $9.37 | +348.24% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 → $7 | $2.04 | +243.14% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $1.86 | +383.87% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $19.76 | +87.25% | 18 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $750 | $0.5216 | n/a | 14 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.023 | n/a | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $155 | $13.83 | n/a | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $105 | $16.65 | n/a | 13 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.1476 | n/a | 13 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $9.91 | n/a | 7 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 | $7.98 | n/a | 25 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $57 | $24.91 | n/a | 8 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $78 → $80 | $64.73 | n/a | 22 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $4 | $10.12 | n/a | 11 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $207 → $225 | $247.69 | n/a | 30 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.98 | n/a | 6 | Aug 25, 2022 |
Opus Genetics
Sep 9, 2026
Rated: Buy
Price Target: $13 → $16
Current: $5.41
Upside: +195.75%
EyePoint
Aug 18, 2026
Downgraded: Hold
Price Target: $65 → $5
Current: $3.45
Upside: +44.93%
Rani Therapeutics Holdings
Aug 18, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $0.756
Upside: +693.65%
Aquestive Therapeutics
Jun 25, 2026
Reiterated: Buy
Price Target: $8
Current: $4.82
Upside: +65.98%
Savara
Jun 3, 2026
Reiterated: Buy
Price Target: $11
Current: $5.13
Upside: +114.42%
Benitec Biopharma
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $11.07
Upside: -
Gossamer Bio
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.96
Upside: -
Keros Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $10.74
Upside: -
Liquidia
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $68.45
Upside: -
Larimar Therapeutics
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $3.93
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $12.46
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $101.45
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $4.17
Upside: -
May 11, 2026
Rated: Hold
Price Target: n/a
Current: $498.48
Upside: -
Apr 27, 2026
Rated: Hold
Price Target: n/a
Current: $3.55
Upside: -
Apr 24, 2026
Reiterated: Buy
Price Target: $105 → $98
Current: $77.64
Upside: +26.22%
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $17.31
Upside: +131.15%
Feb 25, 2026
Reiterated: Buy
Price Target: $62
Current: $42.21
Upside: +46.88%
Jan 23, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $9.37
Upside: +348.24%
Nov 11, 2025
Reiterated: Buy
Price Target: $3 → $7
Current: $2.04
Upside: +243.14%
Nov 11, 2025
Reiterated: Buy
Price Target: $9
Current: $1.86
Upside: +383.87%
Oct 9, 2025
Reiterated: Buy
Price Target: $37
Current: $19.76
Upside: +87.25%
Aug 11, 2025
Reiterated: Buy
Price Target: $750
Current: $0.5216
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.023
Upside: n/a
Jan 10, 2025
Initiated Coverage: Buy
Price Target: $155
Current: $13.83
Upside: n/a
Aug 13, 2024
Reiterated: Hold
Price Target: $105
Current: $16.65
Upside: n/a
Mar 14, 2024
Reiterated: Buy
Price Target: $2
Current: $0.1476
Upside: n/a
Mar 6, 2024
Rated: Buy
Price Target: $29
Current: $9.91
Upside: n/a
Mar 5, 2024
Reiterated: Hold
Price Target: $21
Current: $7.98
Upside: n/a
Mar 1, 2024
Reiterated: Buy
Price Target: $57
Current: $24.91
Upside: n/a
Feb 23, 2024
Reiterated: Hold
Price Target: $78 → $80
Current: $64.73
Upside: n/a
Feb 22, 2024
Reiterated: Buy
Price Target: $7 → $4
Current: $10.12
Upside: n/a
Feb 8, 2024
Rated: Buy
Price Target: $207 → $225
Current: $247.69
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $1.98
Upside: n/a